{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:42:28Z","timestamp":1789036948468,"version":"build-2803163510"},"reference-count":22,"publisher":"Jaypee Brothers Medical Publishing","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.4103\/0972-5229.136075","type":"journal-article","created":{"date-parts":[[2014,7,5]],"date-time":"2014-07-05T06:14:18Z","timestamp":1404540858000},"page":"456-460","source":"Crossref","is-referenced-by-count":13,"title":["Hypomagnesemia in the intensive care unit: Choosing your gastrointestinal prophylaxis, a case report and review of the literature"],"prefix":"10.5005","volume":"18","author":[{"given":"Shweta","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen K.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Mrejen-Shakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","published-online":{"date-parts":[[2014]]},"reference":[{"key":"ref=1","unstructured":"1. Fda.gov. FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton-pump inhibitor drugs (PPIs). Drug Safety Communication. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm245011.htm. \u200a[2011 Mar 02]."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"2. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006;355:1834-6.","DOI":"10.1056\/NEJMc066308"},{"key":"ref=3","unstructured":"3. Globalrph.com. Globalrph: The clinician ultimate reference. Available from: http:\/\/www.globlarph.com\/conversional_si.htm. [Last accessed 2011 Oct 14]."},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"4. Furlanetto TW, Faulhaber GA. Hypomagnesemia and proton pump inhibitors: Below the tip of the iceberg. Arch Intern Med 2011;171:1391-2.","DOI":"10.1001\/archinternmed.2011.199"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"5. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010;56:112-6.","DOI":"10.1053\/j.ajkd.2009.11.019"},{"key":"ref=6","unstructured":"6. Fern\u00e1ndez-Fern\u00e1ndez FJ, Sesma P, Ca\u00ednzos-Romero T, Ferreira-Gonz\u00e1lez L. Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole. Neth J Med 2010;68:329-30."},{"key":"ref=7","unstructured":"7. Bringhurst FR, Demay MB, Krane SM, Kronenberg HM. Bone and mineral metabolism in health and disease. In: Kasper DL, Braunwald E, Faui AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison\u2032s Principles of Internal Medicine. 16 th ed. United States of America: McGraw-Hill Publishers; 2005. p. 2238-49."},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"8. Buckley MS, Leblanc JM, Cawley MJ. Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit. Crit Care Med 2010;38 6 Suppl: S253-64.","DOI":"10.1097\/CCM.0b013e3181dda0be"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"9. Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007;2:366-73.","DOI":"10.2215\/CJN.02960906"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"10. Regolisti G, Cabassi A, Parenti E, Maggiore U, Fiaccadori E. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 2010;56:168-74.","DOI":"10.1053\/j.ajkd.2010.03.013"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"11. Cundy T, Mackay J. Proton pump inhibitors and severe hypomagnesaemia. Curr Opin Gastroenterol 2011;27:180-5.","DOI":"10.1097\/MOG.0b013e32833ff5d6"},{"key":"ref=12","unstructured":"12. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors: A review. Neth J Med 2009;67:169-72."},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"13. Schmitz C, Perraud AL, Fleig A, Scharenberg AM. Dual-function ion channel\/protein kinases: Novel components of vertebrate magnesium regulatory mechanisms. Pediatr Res 2004;55:734-7.","DOI":"10.1203\/01.PDR.0000117848.37520.A2"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"14. Chubanov V, Schlingmann KP, W\u00e4ring J, Heinzinger J, Kaske S, Waldegger S, et al. Hypomagnesemia with secondary hypocalcemia due to a missense mutation in the putative pore-forming region of TRPM6. J Biol Chem 2007;282:7656-67.","DOI":"10.1074\/jbc.M611117200"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"15. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 2008;69:338-41.","DOI":"10.1111\/j.1365-2265.2008.03194.x"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"16. Li M, Du J, Jiang J, Ratzan W, Su LT, Runnels LW, et al. Molecular determinants of Mg2+ and Ca2+ permeability and pH sensitivity in TRPM6 and TRPM7. J Biol Chem 2007;282:25817-30.","DOI":"10.1074\/jbc.M608972200"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"17. Thongon N, Krishnamra N. Omeprazole decreases magnesium transport across Caco-2 monolayers. World J Gastroenterol 2011;17:1574-83.","DOI":"10.3748\/wjg.v17.i12.1574"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"18. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: A clinical case series. QJM 2010;103:387-95.","DOI":"10.1093\/qjmed\/hcq021"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"19. Metz DC, Sostek MB, Ruszniewski P, Forsmark CE, Monyak J, Pisegna JR. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007;102:2648-54.","DOI":"10.1111\/j.1572-0241.2007.01509.x"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"20. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW. Omeprazole and refractory hypomagnesaemia. BMJ 2008;337:a425.","DOI":"10.1136\/bmj.39505.738981.BE"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"21. Fran\u00e7ois M, L\u00e9vy-Bohbot N, Caron J, Durlach V. Chronic use of proton-pump inhibitors associated with giardiasis: A rare cause of hypomagnesemic hypoparathyroidism? Ann Endocrinol (Paris) 2008;69:446-8.","DOI":"10.1016\/j.ando.2008.03.003"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"22. Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med 2009;151:755-6.","DOI":"10.7326\/0003-4819-151-10-200911170-00016"}],"container-title":["Indian Journal of Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijccm.org\/doi\/pdf\/10.4103\/0972-5229.136075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T20:12:07Z","timestamp":1622146327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijccm.org\/doi\/10.4103\/0972-5229.136075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014]]}},"alternative-id":["10.4103\/0972-5229.136075"],"URL":"https:\/\/doi.org\/10.4103\/0972-5229.136075","relation":{},"ISSN":["0972-5229","1998-359X"],"issn-type":[{"value":"0972-5229","type":"print"},{"value":"1998-359X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}